Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 34 of 34 entries
View as:

Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02052648 Org: User:
Start: 03/31/14 End: 06/20/19 Due: 06/20/20

Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01792050 Org: User:
Start: 02/28/13 End: 07/07/17 Due: 07/07/18

Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT02073123 Org: User:
Start: 07/31/14 End: 07/03/19 Due: 07/03/20

Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02460367 Org: User:
Start: 01/31/16 End: 01/13/21 Due: 01/13/22

Immunotherapy Study for Metastatic Renal Cell Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02035358 Org: User:
Start: 05/31/15 End: 01/12/21 Due: 01/12/22

Vaccine Maintenance Treatment for Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00420732 Org: User:
Start: 01/31/07 End: 12/31/14 Due: 12/31/15

Vaccine Study for Surgically Resected Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00569387 Org: User:
Start: 12/31/07 End: 12/31/14 Due: 12/31/15

A Phase 2 Study of CRLX101(NLG207) in Patients With Advanced Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01380769 Org: User:
Start: 06/30/11 End: 10/31/14 Due: 10/31/15

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01072981 Org: User:
Start: 04/30/10 End: 05/31/16 Due: 05/31/17